Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults

International Journal of Hematology

Volumn 102, Issue 1, 2015, Pages 7-11

  Červinek, Libor ^a   Mayer, Jiří ^a,b   Doubek, Michael ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Immune thrombocytopenia; Remission; Sustained response; Thrombopoietin receptor agonists

Indexed keywords

ELTROMBOPAG; ROMIPLOSTIM; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG; FC RECEPTOR; HYBRID PROTEIN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLEEDING TENDENCY; COMORBIDITY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE THROMBOCYTOPENIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; AGED; AGONISTS; CHRONIC DISEASE; METABOLISM; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 84937525476     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1793-1     Document Type: Article

References (15)

1. Donald MA, Kelton JG. Current options for the treatment of idiopathic trombocytopenic purpura. Semin Hematol. 2007;44(Suppl 5):S12–23.
2. British Committee for Standard in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura (ITP) in adults, children and in pregnancy. Br J Haematol. 2003;120:574–96.
3. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–86.
4. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–47.
5. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395–403.
6. Bussel J, Kuter D. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2013;113:2161–71.
7. Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I, et al. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia (ITP): a pooled analysis of 13 clinical trials. Eur J Haematol. 2013;91:423–36.
8. Bussel J, Saleh M. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia. Br J Haematol. 2013;160:538–46.
9. Ghadaki B, Nazi I, Kelton G, Donald MA. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoetin receptor agonist. Transfusion. 2013;53:2807–12.
10. Mahévas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014;165(6):865–9.
11. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–93.
12. Newland A, Cervinek L, Eggermann J, Lefrere F, Kreuzbauer G. Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim—four European case studies. Haematologica. 2011;96:98.
13. González-López TJ, González-Porras JR, Areji M, De Cabo E, Sanchez Gonzalez B, Alonso A, et al. Sustained response after short-medium-term treatment with eltrombopag in patients with ITP. Blood. 2013;122:2323.
14. Bussel J, Wang X, Eisen M. Case studies of remission in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim. Blood. 2013;122:328.
15. Stasi R, Newland A, Godeau B, Priego V, Viallard J-F, Polez Fernandez MF, et al. An interim analysis of a phase 2, single-arm study of platelet responses and remission rates in patients with immune thrombocytopenia (ITP) receiving romiplostim. Blood. 2013;122:1074.